First, it is a good way to prevent enterovirus 71 / EV71 infection by blocking its entry. Since the VP1 protein contains most of the neutralizing epitopes and acts as a major receptor-binding protein, it is an ideal antiviral target against enterovirus 71 / EV71. Researchers are trying to develop specific antibodies against its neutralizing epitopes. Additionally, due to the important role of VP1 conformational change in viral particle disassembly and RNA release, great efforts are put into designing small molecules that target VP1. Second, proteases 2Apro and 3Cpro are also significant antiviral targets considering their roles in processing viral precursor. Antivirals targeting them should have the ability to inhibit viral protein maturation and prevent host protein from protease degradation as well. Third, the 3D polymerase is an alternative antiviral target for specific inhibition of enterovirus 71 / EV71 replication. Fourth, the replication of enterovirus 71 / EV71 also can be suppressed by inhibiting IRES -dependent translation. Fifth, because of the vital role of viral protein 3A and its precursor 3AB in formation of enterovirus replication complex, antivirals targeting them may prevent enterovirus 71 / EV71 replication. Sixth, modulation of host immunity and interferon treatment may help the combat against enterovirus 71 / EV71 invasion.
Fig 5. Overview of EV71 replication and molecular mechanisms of potential inhibitors
|What is Enterovirus 71 (EV71)?||Biological Characteristics of Enterovirus 71 (EV71)|
|Genetic Variations of Enterovirus 71 (EV71)||Clinical Development of Enterovirus 71 (EV71) Vaccine|
|Potential Drug Targets of Enterovirus 71 (EV71)|